Johnson & Johnson (JNJ) Inventory Average (2009 - 2026)
Johnson & Johnson (JNJ) posted Inventory Average of $14.4 billion for Q1 2026, up 1.54% sequentially from $14.2 billion in Q4 2025, and up 14.62% YoY from $12.6 billion in Q1 2025.
Johnson & Johnson (JNJ) Inventory Average (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Inventory Average data on file, last reported at $14.4 billion in Q1 2026.
- Quarterly Inventory Average rose 14.62% year-over-year to $14.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.4 billion (up 14.62% YoY) and the FY2025 annual result came in at $13.3 billion, up 12.74% from the prior year.
- Inventory Average advanced to $14.4 billion in Q1 2026 per JNJ's latest filing, from $14.2 billion in the prior quarter.
- The five-year high for Inventory Average was $14.4 billion in Q1 2026, with the low at $10.4 billion in Q1 2022.
- Average Inventory Average over 5 years is $12.1 billion, with a median of $11.9 billion recorded in 2023.
- Year-over-year, Inventory Average retreated 8.35% in 2024 and rose 14.62% in 2026.
- Johnson & Johnson's Inventory Average stood at $11.6 billion in 2022, then retreated by 3.17% to $11.2 billion in 2023, then advanced by 11.92% to $12.5 billion in 2024, then advanced by 13.14% to $14.2 billion in 2025, then grew by 1.54% to $14.4 billion in 2026.
- Business Quant data shows JNJ's Inventory Average at $14.4 billion in Q1 2026, $14.2 billion in Q4 2025, and $13.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 14.14 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 14.39 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 5.00 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 6.56 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 6.57 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 6.21 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.84 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 10.66 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 2.06 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 14.39 Bn |
| Dec 28, 2025 | 14.17 Bn |
| Sep 28, 2025 | 13.78 Bn |
| Jun 29, 2025 | 13.04 Bn |
| Mar 30, 2025 | 12.55 Bn |
| Dec 29, 2024 | 12.52 Bn |
| Sep 29, 2024 | 12.39 Bn |
| Jun 30, 2024 | 11.78 Bn |
| Mar 31, 2024 | 11.28 Bn |
| Dec 31, 2023 | 11.19 Bn |
| Oct 1, 2023 | 12.04 Bn |
| Jul 2, 2023 | 12.85 Bn |
| Apr 2, 2023 | 11.54 Bn |
| Jan 1, 2023 | 10.97 Bn |
| Oct 2, 2022 | 11.56 Bn |
| Jul 3, 2022 | 11.21 Bn |
| Apr 3, 2022 | 10.69 Bn |
| Jan 2, 2022 | 10.39 Bn |
| Oct 3, 2021 | 10.24 Bn |
| Jul 4, 2021 | 10.03 Bn |